945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
Ren, Z., Huang, Y., Guo, Y., Hou, M.M., Wang, W., Kuang, M., Hao, C., Wang, W., Zhang, Y., Song, T., Dai, C., Hsing-Tao, K., Li, V., Abdrashitov, R., Wang, L., Fan, J.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis
Qin, S., Guo, Y., Meng, Z., Wu, J., Gu, K., Zhang, T., Lin, X., Lin, H., Ying, J-E., Zhou, F., Hsing-Tao, K., Chao, Y., Li, S., Chen, Y., Boisserie, F., Abdrashitov, R., Bai, Y.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Qin, S., Kudo, M., Meyer, T., Finn, R.S., Vogel, A., Bai, Y., Guo, Y., Meng, Z., Zhang, T., Satoh, T., Hiraoka, A., Marino, D., Assenat, E., Wyrwicz, L., Campos, M. Calvo, Hsing-Tao, K., Boisserie, F., Li, S., Chen, Y., Zhu, A.X.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article